10-Q · May 20, 2026
Vivos Therapeutics reported disappointing Q4 results, with actual revenue of $3,824,000 falling significantly short of consensus estimates of $7,258,002, reflecting a 47.31% miss. The company recorded a diluted EPS of…
Earnings analysis · 10-Q
VVOS earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the financial statements or MD&A needed to assess current-quarter revenue, margins, EPS, balance-sheet movements, cash flow, or beat/miss versus the $5.726 million revenue and…
Read full summary
The supplied 10-Q extract does not include the financial statements or MD&A needed to assess current-quarter revenue, margins, EPS, balance-sheet movements, cash flow, or beat/miss versus the $5.726 million revenue and -$0.40 EPS estimates. The filing highlights settlement completion and financing activity, but also emphasizes that the SCN-based operating model remains unproven and that secured debt and financing covenants constrain liquidity. Overall sentiment is bearish because the disclosed risk profile is material and no quantitative operating improvement or guidance is provided in the supplied text.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls assessed as effective
Management stated that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
-
Ortho-Tain litigation settled
The Ortho-Tain litigation was resolved through a confidential settlement and release agreement entered into on March 13, 2026; the agreement also restricts use of “Guide” or “Guides” in formal product names.
-
New financing securities disclosed
The company disclosed issuance of a Series A Convertible Preferred Stock certificate of designation dated July 7, 2026, along with financing-related securities purchase and registration-rights agreements dated June 30, 2026.
What to watch
-
Unproven SCN business model
The new sleep-center sales and distribution model, including the June 2025 SCN acquisition, is described as unproven and supported by limited operating history; the company stated its prior 2024 Rebis Health collaboration did not meet expectations.
-
Debt and financing constraints
The company issued an $8.25 million secured promissory note to finance the SCN acquisition. Although part of the debt was exchanged in August 2026, a portion remains outstanding and secured, while future debt or equity financings above $2.5 million in aggregate require Streeterville consent.
-
Corporate-practice legal exposure
The company warned that its arrangements with SCN physicians could implicate corporate-practice-of-medicine and fee-splitting laws, whose interpretation varies significantly by state; noncompliance could result in penalties, damages, fines, or lost revenue.
Management's outlook
The provided 10-Q extract contains no quantitative revenue or EPS outlook, and no explicit numeric guidance. Outlook deferred/not provided in the supplied filing text.
Earlier filings 4
10-K · April 15, 2026
The company is executing a strategic pivot from a dentist-focused distribution model toward a medical-provider focused model (branded Sleep and Airway Medicine Centers) that includes acquisitions and alliances…
10-Q · August 14, 2024
Vivos Therapeutics reported Q2 revenue of $4,054,000 (three months ended June 30, 2024), up from $3,419,000 in the prior quarter and $3,395,000 in Q2 2023, with gross margin expanding to 65.4% and an improved operating…
10-Q · May 14, 2024
Vivos Therapeutics reported Q1 revenue of $3,419,000 and GAAP net loss of $3,763,000 (loss per share $1.63). Revenue declined versus the prior-year quarter (Q1 2023 revenue $3,857,000) while operating expenses fell to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.